tradingkey.logo

Lung Cancer Patient In Lantern Pharma’s Harmonic Trial Shows Durable Complete Response In Target Cancer Lesions With Survival Continuing For Nearly Two Years

ReutersJun 16, 2025 12:33 PM

- Lantern Pharma Inc LTRN.O:

  • LUNG CANCER PATIENT IN LANTERN PHARMA’S HARMONIC TRIAL SHOWS DURABLE COMPLETE RESPONSE IN TARGET CANCER LESIONS WITH SURVIVAL CONTINUING FOR NEARLY TWO YEARS

  • LANTERN PHARMA INC - NO SIGNIFICANT ADVERSE DRUG REACTIONS OVER 21 CYCLES OF TREATMENT

  • LANTERN PHARMA: ANTICIPATES ADDITIONAL DATA UPDATE FROM RANDOMIZED EXPANSION PHASE IN H2 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI